MarketPeel
Insider Trading Intelligence
JM

Jay M. Moyes

SERA
CHIEF FINANCIAL OFFICER · SERA PROGNOSTICS, INC. · CIK 0001191062
FILING MIX · LIFETIME67%/33%
BUYS
20
SELLS
10
TOTAL VALUE
$933.3K
COMPANIES
5
ACTIVE SINCE
May 2020
HOLDINGS NOW
125,925
AVG SELL PX
$5.91
TRADE KIND
SHOWING 30 / 30
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jay M. Moyes, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+55.56%+2.48%-0.04%+2.52%+0.65%
14d9+44.44%+1.06%+0.75%+0.32%+1.36%
30d9+44.44%+1.15%+2.70%-1.55%-1.67%
60d9+22.22%+3.25%+6.23%-2.98%-3.76%
90d9+44.44%-5.04%+6.56%-9.51%-8.56%
180d9(1 pending)+25.00%+10.61%+12.08%-1.47%-2.16%
1y9(2 pending)+28.57%+7.18%+21.15%-13.96%-23.35%
2y9(3 pending)+50.00%-14.15%+29.05%-43.20%-57.76%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SERA · 35,630 shares · as of Mar 6, 2023
042,06984,138126,206168,27520222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 20 buys / 10 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BCDA
BIOCARDIA, INC.
PURCHASEGRANT
Stock grant
8,00023,573Jul 6, 2026Jul 7, 2026View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
22,000$7.22$158.8K58,322Jun 12, 2026Jun 15, 2026View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00080,322Jun 11, 2026Jun 15, 2026View →
SINT
SINTX TECHNOLOGIES, INC.
PURCHASE
1,000$2.91$2.9K4,000Feb 23, 2026Feb 25, 2026View →
BCDA
BIOCARDIA, INC.
PURCHASEGRANT
Stock grant
12,00015,573Dec 8, 2025Dec 10, 2025View →
SINT
SINTX TECHNOLOGIES, INC.
PURCHASE
3,000$3.59$10.8K3,000Aug 26, 2025Aug 27, 2025View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
22,000$3.40$74.8K53,322Jun 13, 2025Jun 17, 2025View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00075,322Jun 11, 2025Jun 13, 2025View →
BCDA
BIOCARDIA, INC.
PURCHASEGRANT
Stock grant
8293,573Oct 11, 2024Oct 16, 2024View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00048,322Jun 18, 2024Jun 21, 2024View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
22,000$3.34$73.5K21,322Jun 13, 2024Jun 17, 2024View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00043,322Jun 13, 2023Jun 15, 2023View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
22,000$3.45$76.0K16,322Jun 13, 2023Jun 15, 2023View →
SERA
SERA PROGNOSTICS, INC.
PURCHASEGRANT
Stock grant
51,80051,800Mar 6, 2023Mar 7, 2023View →
SERA
SERA PROGNOSTICS, INC.
PURCHASEGRANT
Stock grant
32,80035,630Mar 6, 2023Mar 7, 2023View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
22,858$2.64$60.4K38,322Jun 16, 2022Jun 21, 2022View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00061,180Jun 14, 2022Jun 16, 2022View →
ACHV
ACHIEVE LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
4,4004,400May 31, 2022Jun 1, 2022View →
SERA
SERA PROGNOSTICS, INC.
PURCHASEGRANT
Stock grant
168,275168,275Mar 23, 2022Mar 24, 2022View →
SERA
SERA PROGNOSTICS, INC.
SALE
Chief Financial Officer
3750Jul 19, 2021Jul 21, 2021View →
SERA
SERA PROGNOSTICS, INC.
SALE
Chief Financial Officer
2,4550Jul 19, 2021Jul 21, 2021View →
SERA
SERA PROGNOSTICS, INC.
PURCHASE
Chief Financial Officer
3752,830Jul 19, 2021Jul 21, 2021View →
SERA
SERA PROGNOSTICS, INC.
PURCHASE
Chief Financial Officer
2,4552,455Jul 19, 2021Jul 21, 2021View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,85834,180Jun 15, 2021Jun 17, 2021View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
25,248$11.36$286.9K6,322Jun 10, 2021Jun 11, 2021View →
ACHV
ACHIEVE LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
3,7503,750May 11, 2021May 13, 2021View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
9,703$10.00$97.0K31,570Sep 16, 2020Sep 17, 2020View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE
9,720$9.50$92.3K41,273Jun 16, 2020Jun 17, 2020View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
25,74850,993Jun 9, 2020Jun 10, 2020View →
ACHV
ACHIEVE LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
22,00022,000May 12, 2020May 14, 2020View →
Other insiders · SERA
Loading peer insiders…
About this filer
CIK 0001191062
ROLE
Chief Financial Officer
PRIMARY
SERA
COMPANIES
5
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001191062DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback